Investors Buy Shares of Johnson & Johnson (JNJ) on Weakness

Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Monday. $204.66 million flowed into the stock on the tick-up and $104.09 million flowed out of the stock on the tick-down, for a money net flow of $100.57 million into the stock. Of all companies tracked, Johnson & Johnson had the highest net in-flow for the day. Johnson & Johnson traded down ($1.18) for the day and closed at $126.06

Several equities research analysts have recently issued reports on the company. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. BTIG Research reaffirmed a “sell” rating and issued a $110.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Stifel Nicolaus lifted their target price on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a report on Tuesday, January 23rd. Finally, Citigroup reduced their target price on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a report on Tuesday, February 27th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $142.23.

The company has a market cap of $338.21 billion, a P/E ratio of 17.17, a P/E/G ratio of 1.93 and a beta of 0.74. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47.



Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. The firm had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The company’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.83 earnings per share. equities analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be paid a dividend of $0.90 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.88%. Johnson & Johnson’s dividend payout ratio is currently 46.03%.

In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.22% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Conning Inc. increased its position in shares of Johnson & Johnson by 2.1% during the third quarter. Conning Inc. now owns 358,664 shares of the company’s stock worth $46,630,000 after purchasing an additional 7,245 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Johnson & Johnson by 4.3% during the third quarter. Baillie Gifford & Co. now owns 270,479 shares of the company’s stock worth $35,165,000 after purchasing an additional 11,071 shares in the last quarter. Westpac Banking Corp increased its position in shares of Johnson & Johnson by 1.4% during the third quarter. Westpac Banking Corp now owns 222,633 shares of the company’s stock worth $28,945,000 after purchasing an additional 3,057 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC increased its position in shares of Johnson & Johnson by 3.9% during the third quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,005 shares of the company’s stock worth $4,941,000 after purchasing an additional 1,435 shares in the last quarter. Finally, Sippican Capital Advisors increased its position in shares of Johnson & Johnson by 18.0% during the third quarter. Sippican Capital Advisors now owns 4,329 shares of the company’s stock worth $563,000 after purchasing an additional 660 shares in the last quarter. 67.40% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply